GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alpha Cognition Inc (NAS:ACOG) » Definitions » Notes Receivable

ACOG (Alpha Cognition) Notes Receivable : $0.00 Mil (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Alpha Cognition Notes Receivable?

Alpha Cognition's Notes Receivable for the quarter that ended in Mar. 2025 was $0.00 Mil.


Alpha Cognition Notes Receivable Historical Data

The historical data trend for Alpha Cognition's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alpha Cognition Notes Receivable Chart

Alpha Cognition Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Notes Receivable
- - - - -

Alpha Cognition Quarterly Data
Jan20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Alpha Cognition Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Alpha Cognition Notes Receivable Related Terms

Thank you for viewing the detailed overview of Alpha Cognition's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Alpha Cognition Business Description

Traded in Other Exchanges
N/A
Address
1200 - 750 West Pender Street, Vancouver, BC, CAN, V6C 2T8
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.